Tianjin Zhongxin Pharmaceutical Group Corp Ltd Total Assets
Tianjin Zhongxin Pharmaceutical Group Corp Ltd total assets. Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) holds total assets worth CN¥11.59 Billion CNY (≈ $1.70 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 600329 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)
Total assets of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024. This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total assets have evolved over time, based on quarterly financial data. See Tianjin Zhongxin Pharmaceutical Group Co (600329) stock price for real-time trading data and today's change.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Asset Composition Analysis
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Total Assets Breakdown (December 2024)
Tianjin Zhongxin Pharmaceutical Group Corp Ltd total assets breakdown as of December 2024. Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total assets of CN¥11.59 Billion consist of 61.4% current assets and 38.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 27.3% |
| Accounts Receivable | CN¥1.32 Billion | 12.3% |
| Inventory | CN¥1.29 Billion | 11.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥337.62 Million | 3.1% |
| Goodwill | CN¥12.30 Million | 0.1% |
Asset Composition Trend (1998–2024)
This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 600329 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Zhongxin Pharmaceutical Group Corp Ltd's current assets represent 61.4% of total assets in 2024, an increase from 44.1% in 1998.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2024, up from 21.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 12.3% of total assets.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Total Assets
Key competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.81 | 1.70 | 2.59 |
| Quick Ratio | 2.33 | 1.31 | 1.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.49 Billion | CN¥2.93 Billion | CN¥3.44 Billion |
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Tianjin Zhongxin Pharmaceutical Group Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.69 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | CN¥10.77 Billion |
| Market Capitalization | $3.51 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Zhongxin Pharmaceutical Group Corp Ltd's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tianjin Zhongxin Pharmaceutical Group Corp Ltd's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)
The table below shows the annual total assets of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.77 Billion ≈ $1.58 Billion |
+5.26% |
| 2023-12-31 | CN¥10.23 Billion ≈ $1.50 Billion |
+0.72% |
| 2022-12-31 | CN¥10.16 Billion ≈ $1.49 Billion |
+12.02% |
| 2021-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
+9.46% |
| 2020-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
+5.61% |
| 2019-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
+10.38% |
| 2018-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+7.30% |
| 2017-12-31 | CN¥6.62 Billion ≈ $968.98 Million |
+4.11% |
| 2016-12-31 | CN¥6.36 Billion ≈ $930.77 Million |
+4.81% |
| 2015-12-31 | CN¥6.07 Billion ≈ $888.07 Million |
+11.62% |
| 2014-12-31 | CN¥5.44 Billion ≈ $795.63 Million |
+3.32% |
| 2013-12-31 | CN¥5.26 Billion ≈ $770.04 Million |
+19.04% |
| 2012-12-31 | CN¥4.42 Billion ≈ $646.86 Million |
+6.68% |
| 2011-12-31 | CN¥4.14 Billion ≈ $606.34 Million |
+8.01% |
| 2010-12-31 | CN¥3.84 Billion ≈ $561.40 Million |
+4.62% |
| 2009-12-31 | CN¥3.67 Billion ≈ $536.60 Million |
+6.45% |
| 2008-12-31 | CN¥3.44 Billion ≈ $504.10 Million |
-0.79% |
| 2007-12-31 | CN¥3.47 Billion ≈ $508.10 Million |
-0.98% |
| 2006-12-31 | CN¥3.51 Billion ≈ $513.11 Million |
-13.54% |
| 2005-12-31 | CN¥4.06 Billion ≈ $593.48 Million |
+3.64% |
| 2004-12-31 | CN¥3.91 Billion ≈ $572.63 Million |
+3.06% |
| 2003-12-31 | CN¥3.80 Billion ≈ $555.64 Million |
+26.23% |
| 2002-12-31 | CN¥3.01 Billion ≈ $440.18 Million |
+10.60% |
| 2001-12-31 | CN¥2.72 Billion ≈ $397.98 Million |
+7.60% |
| 2000-12-31 | CN¥2.53 Billion ≈ $369.87 Million |
+74.37% |
| 1999-12-31 | CN¥1.45 Billion ≈ $212.12 Million |
+13.29% |
| 1998-12-31 | CN¥1.28 Billion ≈ $187.24 Million |
-- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more